Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy

British Journal of Ophthalmology

Volumn 92, Issue 6, 2008, Pages 866-867

  Flores Moreno, S ^a   Bautista Paloma, J ^b  

^a Andalusian Agency for Health Technology Assessment Spain   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; VERTEPORFIN;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; FINLAND; GERMANY; HEALTH CARE SYSTEM; HUMAN; ITALY; LETTER; MEDICAL SOCIETY; NEW ZEALAND; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SPAIN; UNITED KINGDOM; UNITED STATES;

ANTIBODIES, MONOCLONAL; HUMANS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 45249101565     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.129296     Document Type: Letter

References (8)

1. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6.
2. Steinbrook R. The price of sight - Ranibizumab, Bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409- 12.
3. Epstein P. Trials that matter: two faces of progress in the treatment of age-related macular degeneration. Ann Intern Med 2007;146:532-4.
4. Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Ophthalmologe 2007;104:588-93.
5. Lazic R, Gabric N. Verteporfin therapy and intravitreal Bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114: 1179-85.
6. Bashshu ZF, Schaka AI, Hama R, et al. Intravitreal Bevacizumab vs Verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-61.
7. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal Bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2007;867:868-56.
8. Algvere PV, Steén B, Seregard S, et al. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol Scand. Published Online First 14 December 2007. doi:10.1111/j.1600-0420. 2007.01113.x.